ACTRN12624000405516招募中1 期
A Phase 1, randomized, double-blind, placebo-controlled single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous BRB-002 in healthy male volunteers
Bitterroot Australia Pty Ltd0 个研究点目标入组 48 人开始时间: 2024年4月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- Male
入选标准
- •1. Written informed consent must be obtained before any assessment is performed
- •2. Male participants aged 18 to 50 years of age (inclusive) at time of signing of informed consent
- •3. Overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests and cardiac evaluation
- •4. Body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive, with minimum and maximum body weights of 50.0 and 120.0 kg, inclusive
排除标准
- •1. Participation in another clinical study of another investigational product within 5 half-lives of enrollment, or within 30 days for small molecules or until the expected pharmacodynamic effect has returned to baseline for biologics, whichever is longer; or longer if required by local regulations
- •2. History of hypersensitivity to any of the IPs or excipients or to drugs of similar chemical classes.
- •3. An active history of clinically significant ECG abnormalities as determined by the Investigator.
- •4. Hemoglobin level below the lower limit of normal. Known or suspected thalassemia trait carriers or a mean corpuscular volume (MCV) outside the range of normal.
- •5. Platelet count below the lower limit of normal.
- •6. Absolute neutrophil count below the lower limit of normal.
- •7. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to IP administration, or longer if required by local regulation.
- •8. Use of nicotine-containing products (e.g., chews tobacco, smokes cigarettes, uses nicotine patch or cigarette-like smoking/vaping implements such as electronic cigarettes, cigarillos, and cigars) within 4 weeks prior to IP administration and for the duration of the study.
- •9. Use of any prescription drugs, including prescribed medicinal use of cannabis/marijuana, and vaccinations within four weeks prior to IP administration, and use of over the counter (OTC) medication, dietary supplements (vitamins included) within one week prior to IP administration.
- •10. Positive urine drug screen (UDS) including recreational cannabis use, urine cotinine, or breath alcohol test at the Screening Visit or upon admission to the Treatment Phase or unwilling to refrain from illicit drugs or nicotine during the study.
- •11. Any history of clinically significant medical or surgical illness requiring hospitalization in the prior 6 months
- •12. History of drug or alcohol abuse within the 12 months prior to IP administration, or evidence of such abuse as indicated by the laboratory assays conducted during screening or baseline.
研究者
相似试验
已完成
不适用
A Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of GX-I7 in HPV-infected female volunteersDiseases of The genitoruinary systemKCT0002389Genexine32
已完成
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm Study of the Safety, Tolerability and Pharmacokinetics of Oral BTD-001 in Healthy VolunteersCognitive impairmentNeurological - Neurodegenerative diseasesACTRN12613000919718Balance Therapeutics Pty Limited30
招募中
1 期
A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single dose of brincidofovir administered intravenously in healthy adult subjectsAdenoviruscytomegalovirussmallpoxInfection - Other infectious diseasesACTRN12616001657415Chimerix, Inc40
已完成
不适用
A Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety, tolerability, pharmacokinetics andDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0002390Genexine50
已完成
不适用
A phase 1, randomized, double-blind, placebo-controlled, multiple dose platform study investigating the immunopharmacology of EDP1815 and EDP2939NL-OMON51644Evelo Biosciences72